ivst_admin – NovAccess Global

Providing Novel Diagnostics & Therapeutics in Cancer and Neurological Diseases

OTC Markets: XSNX

$0.67

+0.09 (15.52%)

June 20, 2021 3:06 PM

OTC Markets: XSNX

$0.67

+0.09

(15.52%)

June 20, 2021 3:18 PM

/

ivst_admin

NovAccess Global Readies for Development of Novel Immunotherapies for Brain Tumor Patients with pre-IND meeting scheduled with the FDA and Files Form 10-K for Fiscal 2020 and Form 10-Q for FQ1/FQ2, 2021

By ivst_adminIn NovAccess Global Press Releases, Press ReleasePosted June 8, 2021

NovAccess Global Secures Worldwide Rights to Approved Patent

By ivst_adminIn NovAccess Global Press ReleasesPosted November 18, 2020

NovAccess Global Enhances Scientific Advisory Board with Distinguished Industry Experts and adds Chief Financial Officer

By ivst_adminIn NovAccess Global Press ReleasesPosted October 21, 2020

NovAccess Global Appoints Dwain Irvin, Ph.D., MPH as New Chief Executive Officer

By ivst_adminIn NovAccess Global Press ReleasesPosted October 15, 2020

NovAccess Global Acquires StemVax Therapeutics from Innovest Global

By ivst_adminIn NovAccess Global Press ReleasesPosted September 9, 2020

XsunX, Inc. Changes Name to NovAccess Global Inc.

By ivst_adminIn NovAccess Global Press ReleasesPosted August 26, 2020

XsunX, Inc. Changes Name to NovAccess Global Inc.

By ivst_adminIn UncategorizedPosted August 26, 2020

Innovest Global Announces Upcoming Conference Participation and Biotech Award

By ivst_adminIn NovAccess Global Press ReleasesPosted September 4, 2019

Innovest Board Approves Plan to Maximize Shareholder Value from Biotech and Industrial Initiatives

By ivst_adminIn NovAccess Global Press ReleasesPosted July 22, 2019

Innovest Global Provides December Shareholder Update Featuring Acquisition Update, Revenue Growth, Biotech Progress

By ivst_adminIn NovAccess Global Press ReleasesPosted December 17, 2018